The FDA has approved Agios Pharmaceuticals' mitapivat (AQVESME) as the first oral treatment for anemia in thalassemia, reducing transfusion needs by 40-50%. Meanwhile, a clinical trial found a three-times-weekly dosing of vadadustat (Vafseo) is safe for kidney dialysis patients, potentially improving convenience.
BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07673302 |
Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia |
RECRUITING | NA |
| NCT07671534 |
Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors |
RECRUITING | PHASE2 |
| NCT06299670 |
Efficacy of Combination of Hdroxyurea and Thalidomide Over Hydroxyurea or Thalidomide in the Treatment of Transfusion Dependent Thalassemia in Children |
COMPLETED | PHASE4 |
| NCT00602641 |
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma |
ACTIVE_NOT_RECRUITING | PHASE3 |
